Hiraga Nanaho, Ando Yosuke, Matsuoka Hiroshi, Nishibe-Toyosato Seira, Mizuno Tomohiro, Katsuno Hidetoshi, Ikeda Yoshiaki, Kawada Kenji, Morise Zenichi, Suda Koichi, Yamada Shigeki
Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan.
College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.
Int J Clin Oncol. 2025 Jun 5. doi: 10.1007/s10147-025-02804-3.
The incidence of chemotherapy-induced nausea and vomiting (CINV) when using an oxaliplatin-based regimen may vary according to the cancer type. This study compared the occurrence of CINV in patients with gastric or colorectal cancers.
This retrospective study included patients who received oxaliplatin-containing regimens for gastric or colorectal cancer. The incidence of CINV during the first treatment course was evaluated. Propensity score matching (PSM) was performed between gastric cancer (GC) and colorectal cancer (CRC) groups to compare the complete response (CR) and total control (TC) rates as indicators of antiemetic efficacy. The impact of primary tumor resection history, surgical procedure, and antiemetic agents was analyzed in the group with a higher incidence of CINV.
The GC group included 99 patients and the CRC group included 180 patients, with 60 patients per group, after PSM. The CR rate was significantly lower in the GC group (75.0%) than in the CRC group (95.0%) (P < 0.01). Before PSM, the TC rate varied significantly by resection type in patients with GC (P = 0.012), indicating that tumor resection influenced the TC rate (P = 0.015). In patients with GC who underwent tumor resection, neither dopamine 2 receptor antagonists (P = 0.090) nor neurokinin 1 receptor antagonist (P = 0.66) use was associated with a significant difference in the CR rate.
Patients with GC have a higher incidence of CINV than those with CRC. In patients with GC, tumor resection significantly influenced the total control rate of CINV.
使用基于奥沙利铂的方案时，化疗引起的恶心和呕吐（CINV）的发生率可能因癌症类型而异。本研究比较了胃癌或结直肠癌患者中CINV的发生情况。
这项回顾性研究纳入了接受含奥沙利铂方案治疗胃癌或结直肠癌的患者。评估了首个疗程中CINV的发生率。在胃癌（GC）组和结直肠癌（CRC）组之间进行倾向评分匹配（PSM），以比较完全缓解（CR）率和总控制（TC）率，作为止吐疗效的指标。在CINV发生率较高的组中，分析了原发肿瘤切除史、手术方式和止吐药物的影响。
PSM后，GC组包括99例患者，CRC组包括180例患者，每组60例。GC组的CR率（75.0%）显著低于CRC组（95.0%）（P < 0.01）。在PSM之前，GC患者的TC率因切除类型而异（P = 0.012），表明肿瘤切除影响了TC率（P = 0.015）。在接受肿瘤切除的GC患者中，使用多巴胺2受体拮抗剂（P = 0.090）和神经激肽1受体拮抗剂（P = 0.66）与CR率的显著差异均无关。
GC患者的CINV发生率高于CRC患者。在GC患者中，肿瘤切除显著影响了CINV的总控制率。
